Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 4/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.35 |
| ▸ | GRK2 | P25098 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | BAD | Q92934 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23124168 | 0.87 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL6217469 | 0.86 | SLC6A2 (0.38) | SLC6A4SLC6A3SLC6A2POLB | |
| SCHEMBL16097281 | 0.86 | SLC6A3 (0.38) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL19128316 | 0.81 | JAK1 (0.39) | SLC6A4SLC6A3SLC6A2POLB | |
| SCHEMBL6991525 | 0.78 | SIGMAR1 (0.36) | SIGMAR1SLC6A4SLC6A3CDK9CCNT1 | |
| Malonic Acid SCHEMBL5194387 | 0.78 | SLC6A3 (0.51) | SIGMAR1SLC6A4SLC6A3SLC6A2CDK9 | |
| SCHEMBL1335541 | 0.76 | SLC6A4 (0.58) | SIGMAR1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL2071679 | 0.75 | POLB (0.52) | POLB | |
| SCHEMBL2071682 | 0.75 | POLB (0.52) | POLB | |
| SCHEMBL23122148 | 0.74 | SLC6A2 (0.37) | SLC6A4SLC6A3SLC6A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160289171-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | SIGMAR1 4400/4885SLC6A4 1491/4885SLC6A3 2394/4885 |
| US-20170231999-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | SIGMAR1 4400/4885SLC6A4 1491/4885SLC6A3 2394/4885 |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | SIGMAR1 3529/4885SLC6A4 874/4885SLC6A3 1502/4885 |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | SIGMAR1 3529/4885SLC6A4 874/4885SLC6A3 1502/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | SIGMAR1 3529/4885SLC6A4 874/4885SLC6A3 1502/4885 |
| US-20160289171-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | SIGMAR1 4400/4885SLC6A4 1491/4885SLC6A3 2394/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | SIGMAR1 3529/4885SLC6A4 874/4885SLC6A3 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.